Antibody forming cells and plasmablasts in peripheral blood in
CVID patients after vaccination

J 2011

Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination

CHOVANCOVÁ, Zita, Marcela VLKOVÁ, Jiří LITZMAN, Jindřich LOKAJ, Vojtěch THON et. al.

Basic information

Original name

Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination

Authors

CHOVANCOVÁ, Zita (203 Czech Republic, belonging to the institution), Marcela VLKOVÁ (203 Czech Republic, belonging to the institution), Jiří LITZMAN (203 Czech Republic, belonging to the institution), Jindřich LOKAJ (203 Czech Republic, belonging to the institution) and Vojtěch THON (203 Czech Republic, guarantor, belonging to the institution)

Edition

Vaccine, 2011, 0264-410X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.766

RIV identification code

RIV/00216224:14110/11:00059060

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.vaccine.2011.03.087

UT WoS

000292176800010

Keywords in English

CVID Tetanus toxoid Pneumococcal vaccine ELISPOT

Abstract

V originále

Common variable immunodeficiency (CVID), the most frequent primary antibody disorder, is characterized by hypogammaglobulinaemia and impaired antibody production. Poor vaccination response is essential for the diagnosis of CVID. Their under laying defects remain to be elucidated. Routine determination of antibody production in serum from CVID patients after vaccination and investigation of B cell function in vivo is complicated due to substitution therapy. Therefore we investigated antibody production on the B-cell level by ELISPOT and characterized changes in B-cell subpopulations in CVID patients, including plasmablasts, in peripheral blood by flow cytometry after vaccination for specification of the diagnosis. Thirty-seven CVID patients and eighty healthy volunteers were immunized with tetanus toxoid and pneumococcal polysaccharide vaccines. Specific antibody levels and B cell subpopulations were measured before vaccination and on day 7 after vaccination by ELISPOT assay and flow cytometry respectively. Of the thirty-seven well defined CVID patients studied, thirty lacked detectable spot forming cells producing specific IgG, IgA or IgM antibodies against employed vaccines and seven had only weak responses compared to controls. In the control group, an increase in circulating plasmablasts on day 7 post immunization corresponded with the appearance of antibody forming cells. In contrast, CVID patients failed to increase plasmablasts significantly in peripheral blood after antigen challenge. Our findings indicate that CVID patients have a block in terminal B-cell differentiation and that flow based assessment of plasmablasts in peripheral blood after vaccination serves as a surrogate diagnostic marker for assessing in vivo antibody responses in patients suspected to have CVID.

Links

7E08062, research and development project

Name: Pathophysiology and Natural Course of Primary Antibody Deficiency (PAD) Syndromes

Investor: Ministry of Education, Youth and Sports of the CR, Pathophysiology and Natural Course of Primary Antibody Deficiency (PAD) Syndromes

Citovat

CHOVANCOVÁ, Zita, Marcela VLKOVÁ, Jiří LITZMAN, Jindřich LOKAJ and Vojtěch THON. Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination. Vaccine. 2011, vol. 29, No 24, p. 4142–4150. ISSN 0264-410X. Available from: https://dx.doi.org/10.1016/j.vaccine.2011.03.087.

@article{950100,
   author = {Chovancová, Zita and Vlková, Marcela and Litzman, Jiří and Lokaj, Jindřich and Thon, Vojtěch},
   article_number = {24},
   doi = {http://dx.doi.org/10.1016/j.vaccine.2011.03.087},
   keywords = {CVID Tetanus toxoid Pneumococcal vaccine ELISPOT},
   language = {eng},
   issn = {0264-410X},
   journal = {Vaccine},
   title = {Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination},
   volume = {29},
   year = {2011}
}

TY  - JOUR
ID  - 950100
AU  - Chovancová, Zita - Vlková, Marcela - Litzman, Jiří - Lokaj, Jindřich - Thon, Vojtěch
PY  - 2011
TI  - Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination
JF  - Vaccine
VL  - 29
IS  - 24
SP  - 4142–4150
EP  - 4142–4150
SN  - 0264410X
KW  - CVID Tetanus toxoid Pneumococcal vaccine ELISPOT
N2  - Common variable immunodeficiency (CVID), the most frequent primary antibody disorder, is characterized by hypogammaglobulinaemia and impaired antibody production. Poor vaccination response is essential for the diagnosis of CVID. Their under laying defects remain to be elucidated. Routine determination of antibody production in serum from CVID patients after vaccination and investigation of B cell function in vivo is complicated due to substitution therapy. Therefore we investigated antibody production on the B-cell level by ELISPOT and characterized changes in B-cell subpopulations in CVID patients, including plasmablasts, in peripheral blood by flow cytometry after vaccination for specification of the diagnosis. Thirty-seven CVID patients and eighty healthy volunteers were immunized with tetanus toxoid and pneumococcal polysaccharide vaccines. Specific antibody levels and B cell subpopulations were measured before vaccination and on day 7 after vaccination by ELISPOT assay and flow cytometry respectively. Of the thirty-seven well defined CVID patients studied, thirty lacked detectable spot forming cells producing specific IgG, IgA or IgM antibodies against employed vaccines and seven had only weak responses compared to controls. In the control group, an increase in circulating plasmablasts on day 7 post immunization corresponded with the appearance of antibody forming cells. In contrast, CVID patients failed to increase plasmablasts significantly in peripheral blood after antigen challenge. Our findings indicate that CVID patients have a block in terminal B-cell differentiation and that flow based assessment of plasmablasts in peripheral blood after vaccination serves as a surrogate diagnostic marker for assessing in vivo antibody responses in patients suspected to have CVID.
ER  -

CHOVANCOVÁ, Zita, Marcela VLKOVÁ, Jiří LITZMAN, Jindřich LOKAJ and Vojtěch THON. Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination. \textit{Vaccine}. 2011, vol.~29, No~24, p.~4142–4150. ISSN~0264-410X. Available from: https://dx.doi.org/10.1016/j.vaccine.2011.03.087.

Detailed Information on Publication Record